

The Promising Results from Lumito's First International Pilot Study Were Presented at Liverpool Pathology 2023

The results from Lumito's first international pilot study show that it is possible to detect the deposition of immunoglobulin and complement in renal tissue using Lumito's technology. The result confirms the expectations that the study was based around and demonstrates that Lumito's technology has the potential to be established in renal diagnostics.

In May, Lumito's first international pilot study, Utility of Upconversion Nanoparticles Based Immunohistochemistry in Diagnostic Renal Biopsies, was completed in collaboration with Dr Kishore Gopalakrishnan's research group at University Hospitals Coventry and Warwickshire NHS Trust in the UK, and last week Dr Kishore Gopalakrishnan presented the results in a poster at Liverpool Pathology 2023.

The concept study aimed to compare the conventional method of DAB staining of renal biopsies with Lumito's immunohistochemical (IHC) method based on upconverted nanoparticles.

"UCNP-based IHC has the potential to become established in renal diagnostic practice and further multicentre studies using the full range of diagnostic antibodies is needed." comments Dr. Kishore Gopalakrishnan.

"The result is a great confirmation that our technology works and further proof that our technology with UCNPs offers clearer and more detailed tissue images than today's traditional technologies." comments Mattias Lundin.

The company and the research group discuss and plan for the next step in this collaboration.

The poster is available on Lumito's website [here](#).

For further information, please contact:

Mattias Lundin, CEO Lumito

E-mail: ml@lumito.se

Ph: +46 76 868 45 09

Lumito

Lumito specialises in medical technology for digital pathology. Through its proprietary and patented technology, Lumito aims to provide healthcare providers with a powerful tool to meet the demands for fast and safe tissue diagnostics in personalised healthcare. The technology enables higher-contrast images without irrelevant background information, making it easier for pathologists to find cancer indications. The technology, based on Up Converting NanoParticles (UCNP), has the potential to significantly improve the diagnosis of tissue samples through higher quality analyses and shortened analysis times. The method has several potential applications, but Lumito has focused primarily on digital pathology and first on a release of SCIZYS by Lumito for use in research laboratories. The company is a spin-off of a research group at the Department of Atomic Physics and Laser Centre. www.lumito.se/en

The share is traded on NGM Nordic SME under the name LUMITO, and Mentor is Mangold Fondkommission.

Attachments

[The Promising Results from Lumito's First International Pilot Study Were Presented at Liverpool Pathology 2023](#)